Northland Securities reissued their buy rating on shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a report published on Friday. Northland Securities currently has a $40.00 price objective on the specialty pharmaceutical company’s stock.
A number of other analysts have also commented on FLXN. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Thursday, July 13th. Royal Bank Of Canada reaffirmed an outperform rating and set a $44.00 target price on shares of Flexion Therapeutics in a report on Thursday, August 10th. Needham & Company LLC reaffirmed a buy rating and set a $36.00 target price (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. BMO Capital Markets reaffirmed a buy rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Finally, ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $98.33.
Shares of Flexion Therapeutics (NASDAQ:FLXN) opened at $23.99 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. Flexion Therapeutics has a fifty-two week low of $15.96 and a fifty-two week high of $32.25.
In other news, insider Michael D. Clayman purchased 5,000 shares of Flexion Therapeutics stock in a transaction dated Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the transaction, the insider now directly owns 35,395 shares in the company, valued at approximately $835,322. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Yamo Deniz purchased 1,375 shares of Flexion Therapeutics stock in a transaction dated Thursday, August 31st. The shares were purchased at an average cost of $25.40 per share, for a total transaction of $34,925.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $127,000. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 10,375 shares of company stock worth $249,575. Insiders own 15.98% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. Fiduciary Trust Co. bought a new stake in Flexion Therapeutics in the 2nd quarter valued at $101,000. IFP Advisors Inc lifted its position in Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,000 shares in the last quarter. Advisor Group Inc. lifted its position in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Flexion Therapeutics in the 3rd quarter valued at $135,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Flexion Therapeutics in the 3rd quarter valued at $235,000. 69.17% of the stock is currently owned by institutional investors and hedge funds.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.